瑞典Ⅱ-Ⅲ期黑色素瘤生存结局与患者特征对比:全国登记研究
基于瑞典黑色素瘤登记等全国数据库,纳入2001至2018年病理确诊的5815例Ⅱ-Ⅲ期皮肤黑色素瘤成人患者,分析各亚期10年黑色素瘤特异性生存率及临床病理、共病与社会经济特征。结果显示ⅡC期生存率(61%)低于ⅢA期(78%),调整年龄、性别和厚度后差异仍显著,提示需重新审视瑞典随访指南。
要点
- ⅡC期10年黑色素瘤特异性生存率61%,低于ⅢA期的78%。
- ⅡC期患者年龄更大、男性更多、共病更多且社会经济地位更低。
- 调整年龄、性别和厚度后ⅡC与ⅢA期生存差异仍显著。
核心结论
- 瑞典ⅡC期局限型黑色素瘤患者的黑色素瘤特异性生存显著差于ⅢA期淋巴结受累患者,且两亚期在年龄、性别、共病和社会经济地位上存在差异。
- 研究提示需改进厚型局限型黑色素瘤的治疗,并建议重新考虑对ⅡC期随访强度低于ⅢA期的现行瑞典指南。
研究设计与样本
- 全国性人群登记研究,纳入2001至2018年病理确诊的5815例瑞典Ⅱ-Ⅲ期皮肤黑色素瘤成人患者。
- 数据来自瑞典黑色素瘤登记、全国死因登记及其他多个全国性人群登记数据库的链接。
- 分析各亚期的临床病理特征、共病和社会经济因素,并计算10年黑色素瘤特异性生存率及95%CI。
- 采用Cox回归评估黑色素瘤特异性生存与亚期的关联,计算粗模型和调整模型的HR及95%CI。
主要发现
- 5815例Ⅱ-Ⅲ期患者10年黑色素瘤特异性生存率:ⅡA期86%、ⅡB期73%、ⅡC期61%、ⅢA期78%、ⅢB期56%、ⅢC期43%、ⅢD期19%。
- ⅡC期患者中位年龄70.0岁、男性59.2%,较ⅢA期(中位年龄55.0岁、男性51.5%)年龄更大、男性更多。
- ⅡC期患者共病更多(如高血压、2型糖尿病)且社会经济地位更低。
- 回归分析显示年龄、性别和厚度差异部分解释了ⅡC与ⅢA期的生存差异,但调整后生存差异仍显著。
关键数值与推荐
- 10年黑色素瘤特异性生存率(95%CI未在原文摘要中给出具体区间):ⅡA期86%、ⅡB期73%、ⅡC期61%、ⅢA期78%、ⅢB期56%、ⅢC期43%、ⅡD期19%。
- ⅡC期中位年龄70.0岁、男性59.2%;ⅢA期中位年龄55.0岁、男性51.5%。
- 调整年龄、性别和厚度后,ⅡC与ⅢA期之间仍存在显著生存差异(HR及95%CI未在摘要中报告)。
临床怎么用
- 临床评估ⅡC期局限型黑色素瘤时应认识到其生存可能差于ⅢA期,不应仅因无淋巴结受累而低估风险。
- 随访强度可结合亚期、年龄、性别、共病及社会经济因素个体化制定,而非单纯按Ⅱ期低于Ⅲ期的原则。
- 厚型局限型黑色素瘤患者可能需要更积极的治疗与随访策略。
局限性
- 原文摘要未报告具体HR值、95%CI及P值。
- 为观察性登记研究,残余混杂可能影响亚期间生存比较。
- 研究对象为瑞典人群,结论外推至其他人群需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Prognostic stratification is essential for guiding treatment and follow-up in cutaneous melanoma. Previous international studies suggest that patients with localized stage IIB and IIC melanoma have poorer survival rates than those with lymph node involvement in stage IIIA. Nevertheless, Swedish guidelines still recommend less frequent follow-up for stage II than for patients with stage III. OBJECTIVES: To evaluate melanoma-specific survival and characteristics of Swedish patients with stage II-III melanoma. METHODS: This study included all Swedish adults diagnosed with stage II-III melanoma (pathologically confirmed) between 31 December 2018 and 1 January 2001. Data were obtained through linkage between the Swedish Melanoma Register, the National Cause of Death Register, and several other nationwide population-based registers. Clinicopathological characteristics, comorbidities and socioeconomic factors, in addition to 10-year melanoma-specific survival rates and their corresponding 95% confidence intervals (CIs), were analysed across substages. Cox regression models assessed the association between melanoma-specific survival and melanoma substages with hazard ratios (HRs) and 95% CIs calculated for both crude and adjusted models. RESULTS: The 10-year melanoma-specific survival rates among 5815 patients with stage II-III melanoma were as follows: IIA, 86%; IIB, 73%; IIC, 61%; IIIA, 78%; IIIB, 56%; IIIC, 43% and IIID, 19%. Patients with stage IIC melanoma (median age 70.0 years, 59.2% male sex) were older, more likely to be male, had more comorbidities (e.g. hypertension, type 2 diabetes) and lower socioeconomic status compared with patients with stage IIIA (median age 55.0 years, 51.5% male sex). Regression analyses revealed that differences in age, sex and thickness contributed to contrasting survival differences between stage IIC and IIIA, but a significant survival difference remained after adjusting for these factors. CONCLUSIONS: Patients in Sweden with localized stage IIC melanoma have significantly worse melanoma-specific survival than those with lymph node involvement in stage IIIA, with stage-specific differences in age, sex, comorbidities and socioeconomic status. These findings underscore the need for better treatment for thick, localized melanoma, and suggest reconsideration of current Swedish guidelines, which currently recommend that patients with stage IIC melanoma receive less intensive follow-up than those with stage IIIA. Melanoma is a form of skin cancer that can spread to other parts of the body and become life-threatening. Melanoma affects around 330,000 people worldwide each year. The severity of melanoma is usually categorized into stages. Stage II and stage III represent more advanced cases. It might seem as though people with stage III melanoma have lower chances of survival than those with stage II. However, this is not always the case. We performed a nationwide study in Sweden to look at the likelihood of survival in people with stage II–III melanoma. We also wanted to better understand the key characteristics of these people. We analysed data from national health registers. Our study focused on all adults diagnosed with stage II and III melanoma in Sweden between 2001 and 2018. We concentrated on understanding factors that might explain this survival difference. These included patient age and other existing health conditions. We also looked at socioeconomic factors like education and income. We found that people with stage IIIA melanoma generally lived longer over the next 10 years compared with those with stage IIC melanoma. People with stage IIIA were often younger and had fewer other health conditions. They were also more likely to have higher levels of education and income. Our findings highlight the need to rethink how we stage and treat people living with melanoma. Understanding the unique characteristics of patients in each disease stage can help clinicians make decisions about treatment and follow-up care. This will ensure that people living with melanoma receive the most appropriate care based on their individual risks.
引用
- Marjanovic M, Mikiver R, Nielsen K, et al. Contrasting survival outcomes and patient characteristics in 5815 patients with stage II and III melanoma: a nationwide population-based registry study from Sweden. Br J Dermatol. 2026. PMID: 41296675. doi:10.1093/bjd/ljaf478
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。